# US 2010/0168125 A1 · Indolizines and aza-analog derivatives thereof as cns active compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168125 A1
- Document ID: US20100168125A1
- Status: Published application
- Kind: A1
- Application number: 12/532,371
- Filed: 2008-03-18
- Published: 2010-07-01
- Earliest claimed: 2007-03-21
- Inventors: Peter Gmeiner; Harald Huebner; Marika Skultety
- Web page: https://patentgrep.com/patent/US20100168125A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 15/10: for impotence
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present application relates to indolizine-based compounds of the general formula (I) and aza-analogs thereof, which have medical utility, for example as antipsychotics.

## Claims

### Claim 1

Compounds of the general formula I,
wherein:
Q1 and Q2 are independently of each other N, CH or C—R1;
Q3 is CH or C—R1 if at least one of Q1 and Q2 is different from nitrogen, and Q3 is selected from CH, C—R1 and N if Q1 and Q2 are both nitrogen;
m is 0, 1, 2 or 3;
any R1 is bonded to a C-atom of the heterocycle of formula I and is independently of each other selected from the group comprising of hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, alkyl, cycloalkyl, alkyloxy, alkylthio, alkenyl, alkynyl, phenyl, heteroaryl, phenoxy, halogen, trifluoromethyl, alkylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, phenylcarbonyl, phenylalkyl, phenylalkyloxy, phenylalkylcarbonyl, phenylalkyloxycarbonyl, alkyloxycarbonyl, alkylsulfonyl, phenylsulfonyl, sulfamoyl, alkylaminosulfonyl, dialkylaminosulfonyl, phenylsulfonylamino and alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, alkyloxy, halogen, alkyl, cycloalkyl, carboxy, NR7R8, cyano, trifluoromethyl and nitro; and wherein each cycloalkyl can be unsubstituted or substituted with hydroxyl, alkyloxy, halogen, alkyl, phenyl, amino and NR7R8.
X is a group having the formula
wherein:
Y is chosen from among S and O;
k is 0, 1 or 2;
n is 1-5;
p is 0, 1 or 2;
q is 1 or 2;
R2, R3, R4, R5 and R6 are in each case and independently of each other selected from the group comprising hydrogen, hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, alkyl, alkyloxy, alkylthio, alkenyl, alkynyl, cycloalkyl, phenyl, heteroaryl, phenoxy, halogen, trifluoromethyl, alkylcarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, phenylcarbonyl, phenylalkyl, phenylalkyloxy, phenylalkylcarbonyl, phenylalkyloxycarbonyl, alkyloxycarbonyl, alkylsulfonyl, phenylsulfonyl, sulfamoyl, alkylaminosulfonyl, dialkylaminosulfonyl, phenylsulfonylamino and alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, alkyloxy, halogen, alkyl, cycloalkyl, carboxy, NR7R8, cyano, trifluormethyl and nitro; and wherein two vicinal residues R2, R3, R4, R5 and R6 together with the C-atoms of the phenyl ring to which they are bonded, can form an oxygen and/or nitrogen-containing 5-, 6- or 7-membered ring;
R7 and R8 are independently selected from hydrogen, alkyl, cycloalkyl, phenyl, heteroaryl, phenylalkyl, alkylsulfonyl, phenylsulfonyl, heteroarylsulfonyl, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, phenylcarbonyl, and heteroarylcarbonyl; wherein each alkyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, alkyloxy, phenyl, fluoro, carboxy, and NR9R10; and wherein R7 and R8 may form a 5- to 7-membered cycle; and wherein each heterocycle is a monocyclic ring and wherein phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, alkyloxy, halogen, alkyl, carboxy, NR9R10, cyano, trifluormethyl and nitro;
R9 and R10 are independently selected from among hydrogen and alkyl;
R11 is hydroxyl, (C1-C3)alkyl, hydroxy-(C1-C3)alkyl, halogen-(C1-C3)alkyl or oxo;
provided that the heterocycle of formula I carries precisely one group X;
in the form of the free base, their physiologically acceptable salts, possible conformational isomers, enantiomers, and diastereomers.

### Claim 2 (depends on 1)

A compound according to claim 1, selected from the group of formulas IIa-IId
wherein:
m is 0, 1, 2 or 3;
any R1 is bonded to a C-atom of a heterocycle of formulas IIa-IId and is independently of each other selected from the group comprising of hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, (C1-C10)alkyl, (C3-C7) cycloalkyl, (C1-C10)alkyloxy, (C1-C10)alkylthio, (C2-C10)alkenyl, (C2-C10)alkynyl, phenyl, heteroaryl, phenoxy, halogen, trifluoromethyl, (C1-C10)alkylcarbonyl, (C1-C10)alkylaminocarbonyl, di(C1-C10)alkylaminocarbonyl, phenylcarbonyl, phenyl(C1-C10)alkyl, phenyl(C1-C10)alkyloxy, phenyl(C1-C10)alkylcarbonyl, phenyl(C1-C10)alkyloxycarbonyl, (C1-C10)alkyloxycarbonyl, (C1-C10)alkylsulfonyl, phenylsulfonyl, sulfamoyl, (C1-C10)alkylaminosulfonyl, di(C1-C10)alkylaminosulfonyl, phenylsulfonylamino, and (C1-C10)alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, (C3-C7) cycloalkyl, carboxy, NR7R8, cyano, trifluoromethyl, and nitro;
X is a group having the formula
wherein:
k is 0, 1 or 2;
n is 1-5;
p is 0, 1 or 2;
q is 1 or 2;
R2, R3, R4, R5 and R6 are in each case and independently of each other selected from the group comprising hydrogen, hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, (C1-C10)alkyl, (C3-C7)cycloalkyl, (C1-C10)alkyloxy, (C1-C10)alkylthio, (C2-C10)alkenyl, (C2-C10)alkynyl, phenyl, heteroaryl, phenoxy, halogen, trifluoromethyl, (C1-C10)alkylcarbonyl, (C1-C10)alkylaminocarbonyl, di(C1-C10)alkylaminocarbonyl, phenylcarbonyl, phenyl(C1-C10)alkyl, phenyl(C1-C10)alkyloxy, phenyl(C1-C10)alkylcarbonyl, phenyl(C1-C10)alkyloxycarbonyl, (C1-C10)alkyloxycarbonyl, (C1-C19)alkylsulfonyl, phenylsulfonyl, sulfamoyl, (C1-C10)alkylaminosulfonyl, di(C1-C10)alkylaminosulfonyl, phenylsulfonylamino, and (C1-C10)alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, (C3-C7)cycloalkyl, carboxy, NR7R8, cyano, trifluoromethyl, and nitro; and wherein two vicinal residues R2, R3, R4, R5 and R6 together with the C-atoms of the phenyl ring to which they are bonded, can form an oxygen and/or nitrogen-containing 5-, 6- or 7-membered ring;
R7 and R8 are independently selected from hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl; phenyl, heteroaryl, phenyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl, phenylsulfonyl, heteroarylsulfonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkyloxycarbonyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, phenylcarbonyl, and heteroarylcarbonyl; wherein each alkyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, phenyl, fluoro, carboxy, and NR9R10; and wherein R7 and R8 may form a 5- to 7-membered cycle; and wherein each heterocycle is a monocyclic ring and wherein each phenyl or heteroaryl be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, carboxy, NR9R10, cyano, trifluoromethyl, and nitro;
R9 and R10 are independently selected from among hydrogen, and alkyl;
R11 is methyl, ethyl, hydroxyl, hydroxymethyl, or oxo;
provided that each heterocycle of formulas IIa-IId carries precisely one group X;
in the form of the free base, their physiologically acceptable salts and possible enantiomers and diastereomers.

### Claim 3

A compound according to anyone of the preceding claims, wherein q is 1.

### Claim 4

A compound according to anyone of the preceding claims, wherein k is 0.

### Claim 5

A compound according to anyone of the preceding claims, wherein R4 is hydrogen.

### Claim 6

A compound according to anyone of the preceding claims, wherein
m is 0, 1 or 2;
p is 0 or 1;
n is 2, 3 or 4;
each R1 is independently selected from hydrogen, formyl, cyano, oxime, (C1-C3)alkylcarbonyl, (C1-C3)alkyloxycarbonyl, chloro, bromo, iodo, hydroxymethyl, nitro, NR7R8;
wherein R7 and R8 are selected from among hydrogen, (C1-C3)alkyl, (C1-C3)alkylcarbonyl and phenyl(C1-C3)alkyl.

### Claim 7

A compound according to anyone of the preceding claims, wherein
m is 0, 1 or 2;
p is 0 or 1;
n is 2, 3 or 4;
R2 and R3 are independently selected from among hydrogen, fluoro, chloro, bromo, trifluoromethyl, (C1-C3)alkyloxy, (C1-C3)alkyl, —NR7R8, or R2 and R3 form together with the phenylring to which they are attached a dihydrobenzofurane, chromane, tetrahydrobenzoxepine or benzodioxole group;
R4 is selected from hydrogen, (C1-C3)alkyloxy, hydroxy, chloro, fluoro, trifluoromethyl, or NR7R8;
R5 and R6 are independently selected from hydrogen, or fluoro;
wherein R7 and R8 are independently selected from hydrogen, (C1-C3)alkylcarbonyl, (C1-C3)alkyl, and phenyl(C1-C3)alkyl.

### Claim 8

A compound according to anyone of the preceding claims, having the formula IIa
wherein:
R1, X, and m have the meaning as described in the previous claims.

### Claim 9 (depends on 7)

A compound according to claim 7, wherein X is bonded to the 2-, 4-, 5- or 6-position of the heteroaromatic ring system of formula IIa.

### Claim 10 (depends on 7, 8)

A compound according to anyone of claims 7-8, wherein m is 1, and R1 is in 3-position of the heteroaromatic ring system of the general formula IIa.

### Claim 11

A compound according to anyone of the preceding claims, wherein X is
and wherein p is 0 or 1, and the sum of p and n is 3;
R2-R6 have the meaning as defined in any of the preceding claims.

### Claim 12 (depends on 1)

A compound according to claim 1, and having the formula III
wherein:
k is 0, 1, or 2;
m is 0, 1, 2 or 3;
n is 1-5;
p is 0, 1 or 2;
q is 1 or 2, and is preferably 1;
any R1 is bonded to a C-atom of the heterocycle of formula III, and is independently of each other selected from the group comprising of hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, (C1-C10)alkyl, (C3-C6)cycloalkyl, (C1-C10)alkyloxy, (C1-C10)alkylthio, (C2-C10)alkenyl, (C2-C10)alkynyl, phenyl, heteroaryl, phenoxy, halogen, trifluoromethyl, (C1-C10)alkylcarbonyl, (C1-C10)alkylaminocarbonyl, di(C1-C10)alkylaminocarbonyl, phenylcarbonyl, phenyl(C1-C10)alkyl, phenyl(C1-C10)alkyloxy, phenyl(C1-C10)alkylcarbonyl, phenyl(C1-C10)alkyloxycarbonyl, (C1-C10)alkyloxycarbonyl, (C1-C10)alkylsulfonyl, phenylsulfonyl, sulfamoyl, (C1-C10)alkylaminosulfonyl, di(C1-C10)alkylaminosulfonyl, phenylsulfonylamino, and (C1-C10)alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NR7R8, cyano, trifluoromethyl, and nitro;
R2, R3, R4, R5 and R6 are in each case and independently of each other selected from the group comprising hydrogen, hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, (C1-C10)alkyl, (C3-C6)cycloalkyl, (C1-C10)alkyloxy, (C1-C10)alkylthio, (C2-C10)alkenyl, (C2-C10)alkynyl, phenyl, heteroaryl, phenoxy, halogen, trifluoromethyl, (C1-C10)alkylcarbonyl, (C1-C10)alkylaminocarbonyl, di(C1-C10)alkylaminocarbonyl, phenylcarbonyl, phenyl(C1-C10)alkyl, phenyl(C1-C10)alkyloxy, phenyl(C1-C10)alkylcarbonyl, phenyl(C1-C10)alkyloxycarbonyl, (C1-C10)alkyloxycarbonyl, (C1-C19)alkylsulfonyl, phenylsulfonyl, sulfamoyl, (C1-C10)alkylaminosulfonyl, di(C1-C10)alkylaminosulfonyl, phenylsulfonylamino, and (C1-C10)alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NR7R8, cyano, trifluoromethyl, and nitro; and wherein two vicinal residues R2, R3, R4, R5 and R6 together with the C-atoms of the phenyl ring to which they are bonded, can form an oxygen and/or nitrogen-containing 5-, 6- or 7-membered ring;
R7 and R8 are independently selected from hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, phenyl, heteroaryl, phenyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl, phenylsulfonyl, heteroarylsulfonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkyloxycarbonyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, phenylcarbonyl, and heteroarylcarbonyl; wherein each alkyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, phenyl, fluoro, carboxy, and NR9R10; and wherein R7 and R8 may form a 5- to 7-membered cycle; and wherein each heterocycle is a monocyclic ring and wherein each phenyl or heteroaryl be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, carboxy, NR9R10, cyano, trifluoromethyl, and nitro;
R9 and R10 are independently selected from among hydrogen, and alkyl;
R11 is methyl, ethyl, hydroxyl, hydroxymethyl, or oxo;
provided that the heterocycle of formula III carries precisely one group X;
in the form of the free base, their physiologically acceptable salts and possible enantiomers and diastereomers.

### Claim 13 (depends on 12)

A compound according to claim 12, wherein
k is 0 or 1;
m is 0, 1 or 2;
p is 0 or 1;
n is 2, 3 or 4;
q is 1;
each R1 is independently selected from hydrogen, formyl, cyano, oxime, (C1-C3)alkylcarbonyl, (C1-C3)alkyloxycarbonyl, chloro, bromo, iodo, hydroxymethyl, nitro, NR7R8;
R2 and R3 are independently selected from among hydrogen, fluoro, chloro, bromo, trifluoromethyl, (C1-C3)alkyloxy, (C1-C3)alkyl, —NR7R8, or R2 and R3 form together with the phenylring to which they are attached a dihydrobenzofurane, chromane, tetrahydrobenzoxepine or benzodioxole group;
R4 is selected from hydrogen, (C1-C3)alkyloxy, hydroxy, chloro, fluoro, trifluoromethyl, or NR7R8;
R5 and R6 are independently selected from hydrogen, or fluoro;
wherein R7 and R8 are independently selected from hydrogen, (C1-C3)alkylcarbonyl, (C1-C3)alkyl, and phenyl(C1-C3)alkyl.

### Claim 14 (depends on 12, 13)

A compound according to claim 12 or 13, wherein
k is 0;
m is 0 or 1;
n is 3;
p is 0;
q is 1;
R1 is hydrogen, or formyl,
R2 and R3 are independently selected from hydrogen, methoxy, chloro, amino, and acetylamino;
R4, R5 and R6 are all hydrogen.

### Claim 15 (depends on 1)

A compound according to claim 1, and having the formula IV
wherein:
k is 0, 1 or 2;
m is 0, 1, 2 or 3;
n is 1-5;
p is 0, 1 or 2;
q is 1 or 2, and is preferably 1;
any R1 is bonded to a C-atom of the heterocycle of formula IV, and is independently of each other selected from the group comprising of hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, (C1-C10)alkyl, (C3-C6)cycloalkyl, (C1-C10)alkyloxy, (C1-C10)alkylthio, (C2-C10)alkenyl, (C2-C10)alkynyl, phenyl, heteroaryl, phenoxy, halogen, trifluoromethyl, (C1-C10)alkylcarbonyl, (C1-C10)alkylaminocarbonyl, di(C1-C10)alkylaminocarbonyl, phenylcarbonyl, phenyl(C1-C10)alkyl, phenyl(C1-C10)alkyloxy, phenyl(C1-C10)alkylcarbonyl, phenyl(C1-C10)alkyloxycarbonyl, (C1-C10)alkyloxycarbonyl, (C1-C10)alkylsulfonyl, phenylsulfonyl, sulfamoyl, (C1-C10)alkylaminosulfonyl, di(C1-C10)alkylaminosulfonyl, phenylsulfonylamino, and (C1-C10)alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NR7R8, cyano, trifluoromethyl, and nitro;
R2, R3, R4, R5 and R6 are in each case and independently of each other selected from the group comprising hydrogen, hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, (C1-C10)alkyl, (C3-C6)cycloalkyl, (C1-C10)alkyloxy, (C1-C10)alkylthio, (C2-C10)alkenyl, (C2-C10)alkynyl, phenyl, heteroaryl, phenoxy, halogen, trifluoromethyl, (C1-C10)alkylcarbonyl, (C1-C10)alkylaminocarbonyl, di(C1-C10)alkylaminocarbonyl, phenylcarbonyl, phenyl(C1-C10)alkyl, phenyl(C1-C10)alkyloxy, phenyl(C1-C10)alkylcarbonyl, phenyl(C1-C10)alkyloxycarbonyl, (C1-C10)alkyloxycarbonyl, (C1-C19)alkylsulfonyl, phenylsulfonyl, sulfamoyl, (C1-C10)alkylaminosulfonyl, di(C1-C10)alkylaminosulfonyl, phenylsulfonylamino, and (C1-C10)alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NR7R8, cyano, trifluoromethyl, and nitro; and wherein two vicinal residues R2, R3, R4, R5 and R6 together with the C-atoms of the phenyl ring to which they are bonded, can form an oxygen and/or nitrogen-containing 5-, 6- or 7-membered ring;
R7 and R8 are independently selected from hydrogen, (C1-C6)alkyl, (C3-C7)cycloalkyl, phenyl, heteroaryl, phenyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl, phenylsulfonyl, heteroarylsulfonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkyloxycarbonyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, phenylcarbonyl, and heteroarylcarbonyl; wherein each alkyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, phenyl, fluoro, carboxy, and NR9R10; and wherein R7 and R8 may form a 5- to 7-membered cycle; and wherein each heterocycle is a monocyclic ring and wherein each phenyl or heteroaryl be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, carboxy, NR9R10, cyano, trifluoromethyl, and nitro;
R9 and R10 are independently selected from among hydrogen, and alkyl;
R11 is methyl, ethyl, hydroxyl, hydroxymethyl, or oxo;
provided that the heterocycle of formula IV carries precisely one group X;
in the form of the free base, their physiologically acceptable salts and possible enantiomers and diastereomers.

### Claim 16 (depends on 15)

A compound according to claim 15, wherein
k is 0 or 1;
m is 0, 1 or 2;
p is 0 or 1;
n is 2, 3 or 4;
q is 1;
each R1 is independently selected from hydrogen, formyl, cyano, oxime, (C1-C3)alkylcarbonyl, (C1-C3)alkyloxycarbonyl, chloro, bromo, iodo, hydroxymethyl, nitro, NR7R8;
R2 and R3 are independently selected from among hydrogen, fluoro, chloro, bromo, trifluoromethyl, (C1-C3)alkyloxy, (C1-C3)alkyl, —NR7R8, or R2 and R3 form together with the phenylring to which they are attached a dihydrobenzofurane, chromane, tetrahydrobenzoxepine or benzodioxole group;
R4 is selected from hydrogen, (C1-C3)alkyloxy, hydroxy, chloro, fluoro, trifluoromethyl, or NR7R8;
R5 and R6 are independently selected from hydrogen, or fluoro;
wherein R7 and R8 are independently selected from hydrogen, (C1-C3)alkylcarbonyl, (C1-C3)alkyl, and phenyl(C1-C3)alkyl.

### Claim 17 (depends on 15, 16)

A compound according to claim 15 or 16, wherein
k is 0;
m is 0 or 1;
n is 3;
p is 0;
q is 1;
R1 is hydrogen, or formyl, cyano, oxime, (C1-C3)alkyloxycarbonyl, chloro, bromo, iodo, hydroxymethyl, nitro, NR7R8;
R2 and R3 are independently selected from hydrogen, methoxy, chloro, amino, and acetylamino;
R4 is selected from hydrogen, fluoro and chloro
R5 and R6 are both hydrogen.

### Claim 18 (depends on 1)

A compound according to claim 1, and having the formula V
wherein
k is 0, 1 or 2;
m is 0, 1, 2 or 3;
n is 1-5;
p is 0, 1 or 2;
q is 1 or 2, and is preferably 0;
any R1 is bonded to a C-atom of the heterocycle of formulas V, and is independently of each other selected from the group comprising of hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, (C1-C10)alkyl, (C3-C6)cycloalkyl, (C1-C10)alkyloxy, (C1-C10)alkylthio, (C2-C10)alkenyl, (C2-C10)alkynyl, phenyl, heteroaryl, phenoxy, halogen, trifluoromethyl, (C1-C10)alkylcarbonyl, (C1-C10)alkylaminocarbonyl, di(C1-C10)alkylaminocarbonyl, phenylcarbonyl, phenyl(C1-C10)alkyl, phenyl(C1-C10)alkyloxy, phenyl(C1-C10)alkylcarbonyl, phenyl(C1-C10)alkyloxycarbonyl, (C1-C10)alkyloxycarbonyl, (C1-C10)alkylsulfonyl, phenylsulfonyl, sulfamoyl, (C1-C10)alkylaminosulfonyl, di(C1-C10)alkylaminosulfonyl, phenylsulfonylamino, and (C1-C10)alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NR7R8, cyano, trifluoromethyl, and nitro;
R2, R3, R4, R5 and R6 are in each case and independently of each other selected from the group comprising hydrogen, hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, (C1-C10)alkyl, (C1-C10)alkyloxy, (C1-C10)alkylthio, (C2-C10)alkenyl, (C2-C10)alkynyl, phenyl, (C3-C6)cycloalkyl, heteroaryl, phenoxy, halogen, trifluoromethyl, (C1-C10)alkylcarbonyl, (C1-C10)alkylaminocarbonyl, di(C1-C10)alkylaminocarbonyl, phenylcarbonyl, phenyl(C1-C10)alkyl, phenyl(C1-C10)alkyloxy, phenyl(C1-C10)alkylcarbonyl, phenyl(C1-C10)alkyloxycarbonyl, (C1-C10)alkyloxycarbonyl, (C1-C19)alkylsulfonyl, phenylsulfonyl, sulfamoyl, (C1-C10)alkylaminosulfonyl, di(C1-C10)alkylaminosulfonyl, phenylsulfonylamino, and (C1-C10)alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NR7R8, cyano, trifluoromethyl, and nitro; and wherein two vicinal residues R2, R3, R4, R5 and R6 together with the C-atoms of the phenyl ring to which they are bonded, can form an oxygen and/or nitrogen-containing 5-, 6- or 7-membered ring;
R7 and R8 are independently selected from hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, phenyl, heteroaryl, phenyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl, phenylsulfonyl, heteroarylsulfonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkyloxycarbonyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, phenylcarbonyl, and heteroarylcarbonyl; wherein each alkyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, phenyl, fluoro, carboxy, and NR9R10; and wherein R7 and R8 may form a 5- to 7-membered cycle; and wherein each heterocycle is a monocyclic ring and wherein each phenyl or heteroaryl be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, carboxy, NR9R10, cyano, trifluoromethyl, and nitro;
R9 and R10 are independently selected from among hydrogen, and alkyl;
R11 is methyl, ethyl, hydroxyl, hydroxymethyl, or oxo;
provided that the heterocycle of formula V carries precisely one group X;
in the form of the free base, their physiologically acceptable salts and possible enantiomers and diastereomers.

### Claim 19 (depends on 18)

A compound according to claim 18, wherein
k is 0 or 1;
m is 0, 1 or 2;
p is 0 or 1;
n is 2, 3 or 4;
q is 1;
each R1 is independently selected from hydrogen, formyl, cyano, oxime, (C1-C3)alkylcarbonyl, (C1-C3)alkyloxycarbonyl, chloro, bromo, iodo, hydroxymethyl, nitro, NR7R8;
R2 and R3 are independently selected from among hydrogen, fluoro, chloro, bromo, trifluoromethyl, (C1-C3)alkyloxy, (C1-C3)alkyl, —NR7R8, or R2 and R3 form together with the phenylring to which they are attached a dihydrobenzofurane, chromane, tetrahydrobenzoxepine or benzodioxole group;
R4 is selected from hydrogen, (C1-C3)alkyloxy, hydroxy, chloro, fluoro, trifluoromethyl, or NR7R8;
R5 and R6 are independently selected from hydrogen, or fluoro;
wherein R7 and R8 are independently selected from hydrogen, (C1-C3)alkylcarbonyl, (C1-C3)alkyl, and phenyl(C1-C3)alkyl.

### Claim 20 (depends on 18, 19)

A compound according to claim 18 or 19, wherein
K is 0;
m is 0 or 1
n is 3;
p is 0;
q is 1;
R1 is hydrogen, or formyl,
R2 and R3 are independently selected from hydrogen, methoxy, chloro, amino, and acetylamino;
R4, R5 and R6 are all hydrogen.

### Claim 21 (depends on 1)

A compound according to claim 1, and having the formula VI, VII or VIII
wherein:
k is 0, 1 or 2;
m is 0, 1, 2 or 3;
n is 1-5;
p is 0, 1 or 2;
q is 1 or 2, and is preferably 1;
any R1 is bonded to a C-atom of the heterocycle of formula VI, VII or VIII, and is independently of each other selected from the group comprising of hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, (C1-C10)alkyl, (C3-C6)cycloalkyl, (C1-C10)alkyloxy, (C1-C10)alkylthio, (C2-C10)alkenyl, (C2-C10)alkynyl, phenyl, heteroaryl, phenoxy, halogen, trifluoromethyl, (C1-C10)alkylcarbonyl, (C1-C10)alkylaminocarbonyl, di(C1-C10)alkylaminocarbonyl, phenylcarbonyl, phenyl(C1-C10)alkyl, phenyl(C1-C10)alkyloxy, phenyl(C1-C10)alkylcarbonyl, phenyl(C1-C10)alkyloxycarbonyl, (C1-C10)alkyloxycarbonyl, (C1-C10)alkylsulfonyl, phenylsulfonyl, sulfamoyl, (C1-C10)alkylaminosulfonyl, di(C1-C10)alkylaminosulfonyl, phenylsulfonylamino, and (C1-C10)alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NR7R8, cyano, trifluoromethyl, and nitro;
R2, R3, R4, R5 and R6 are in each case and independently of each other selected from the group comprising hydrogen, hydroxy, formyl, oxime, cyano, nitro, amino, NR7R8, carboxy, carbamoyl, (C1-C10)alkyl, (C1-C10)alkyloxy, (C1-C10)alkylthio, (C2-C10)alkenyl, (C2-C10)alkynyl, phenyl, (C3-C6)cycloalkyl, heteroaryl, phenoxy, halogen, trifluoromethyl, (C1-C10)alkylcarbonyl, (C1-C10)alkylaminocarbonyl, di(C1-C10)alkylaminocarbonyl, phenylcarbonyl, phenyl(C1-C10)alkyl, phenyl(C1-C10)alkyloxy, phenyl(C1-C10)alkylcarbonyl, phenyl(C1-C10)alkyloxycarbonyl, (C1-C10)alkyloxycarbonyl, (C1-C19)alkylsulfonyl, phenylsulfonyl, sulfamoyl, (C1-C10)alkylaminosulfonyl, di(C1-C10)alkylaminosulfonyl, phenylsulfonylamino, and (C1-C10)alkylsulfonylamino; wherein each alkyl, alkenyl or alkynyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, and NR7R8; and wherein each heteroaryl is a monocyclic ring and wherein each phenyl or heteroaryl can be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, carboxy, NR7R8, cyano, trifluoromethyl, and nitro; and wherein two vicinal residues R2, R3, R4, R5 and R6 together with the C-atoms of the phenyl ring to which they are bonded, can form an oxygen and/or nitrogen-containing 5-, 6- or 7-membered ring;
R7 and R8 are independently selected from hydrogen, (C1-C6)alkyl, (C3-C6)cycloalkyl, phenyl, heteroaryl, phenyl(C1-C6)alkyl, (C1-C6)alkylsulfonyl, phenylsulfonyl, heteroarylsulfonyl, (C1-C6)alkylcarbonyl, (C1-C6)alkyloxycarbonyl, aminocarbonyl, (C1-C6)alkylaminocarbonyl, phenylcarbonyl, and heteroarylcarbonyl; wherein each alkyl may be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, phenyl, fluoro, carboxy, and NR9R10; and wherein R7 and R8 may form a 5- to 7-membered cycle; and wherein each heterocycle is a monocyclic ring and wherein each phenyl or heteroaryl be unsubstituted or substituted with one or more residues selected from among hydroxyl, (C1-C6)alkyloxy, halogen, (C1-C6)alkyl, carboxy, NR9R10, cyano, trifluoromethyl, and nitro;
R9 and R10 are independently selected from among hydrogen, and alkyl;
R11 is methyl, ethyl, hydroxyl, hydroxymethyl, or oxo;
provided that the heterocycle of any compound of formula VI, VII or VIII carries precisely one group X;
in the form of the free base, their physiologically acceptable salts and possible enantiomers and diastereomers.

### Claim 22 (depends on 21)

A compound according to claim 21, wherein
k is 0 or 1;
m is 0, 1 or 2;
p is 0 or 1;
n is 2, 3 or 4;
q is 1;
each R1 is independently selected from hydrogen, formyl, cyano, oxime, (C1-C3)alkylcarbonyl, (C1-C3)alkyloxycarbonyl, chloro, bromo, iodo, hydroxymethyl, nitro, NR7R8;
R2 and R3 are independently selected from among hydrogen, fluoro, chloro, bromo, trifluoromethyl, (C1-C3)alkyloxy, (C1-C3)alkyl, —NR7R8, or R2 and R3 form together with the phenylring to which they are attached a dihydrobenzofurane, chromane, tetrahydrobenzoxepine or benzodioxole group;
R4 is selected from hydrogen, (C1-C3)alkyloxy, hydroxy, chloro, fluoro, trifluoromethyl, or NR7R8;
R5 and R6 are independently selected from hydrogen, or fluoro;
wherein R7 and R8 are independently selected from hydrogen, (C1-C3)alkylcarbonyl, (C1-C3)alkyl, and phenyl(C1-C3)alkyl.

### Claim 23 (depends on 21, 22)

A compound according to claim 21 or 22, wherein
k is 0;
m is 0 or 1;
n is 3;
p is 0;
q is 1;
R1 is hydrogen, or formyl,
R2 and R3 are independently selected from hydrogen, methoxy, chloro, amino, and acetylamino;
R4, R5 and R6 are all hydrogen.

### Claim 24

A compound selected from
2-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
2-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
2-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
2-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
2-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
2-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
4-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
4-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
4-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
4-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
4-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
4-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[3-[4-(2,3-Dichlorophenyl)piperazin-1-yl]propoxymethyl]pyrazolo[1,5-a]pyridine
5-[3-[4-(2,3-Dichlorophenyl)piperazin-1-yl]propoxymethyl]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
5-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
5-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
5-[4-[4-(4-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
5-[4-[4-(4-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
5-[4-[4-(4-Hydroxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-[4-(4-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-[4-(4-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-[4-(4-Hydroxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
1-[5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-yl]ethanone
1-[5-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-yl]ethanone
1-[5-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-yl]ethanone
(s-trans)-5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde oxime
(s-trans)-5-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde oxime
(s-trans)-5-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde oxime
(s-cis)-5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde oxime
(s-cis)-5-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde oxime
(s-cis)-5-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde oxime
5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbonitrile
5-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbonitrile
5-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbonitrile
5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carboxylic acid ethyl ester
5-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carboxylic acid ethyl ester
5-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carboxylic acid ethyl ester
3-Bromo-5-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
3-Bromo-5-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
3-Bromo-5-[4-[4-(2-chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
3-Chloro-5-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
3-Chloro-5-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
3-Chloro-5-[4-[4-(2-chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]-3-iodopyrazolo[1,5-a]pyridine
3-Iodo-5-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
5-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]-3-iodopyrazolo[1,5-a]pyridine
6-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
6-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
6-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
6-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
6-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
6-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
7-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
7-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
7-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
7-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
7-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
7-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
7-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]tetrazolo[1,5-a]pyridine
7-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]tetrazolo[1,5-a]pyridine
7-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]tetrazolo[1,5-a]pyridine
5-[4-[4-(3-Trifluoromethylphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
5-[4-[4-(3-Nitrophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
5-[4-[4-(3-Aminophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
N-[3-[4-[4-(Pyrazolo[1,5-a]pyridin-5-yloxy)butyl]piperazin-1-yl]phenyl]acetamide
5-[4-[4-(3-Trifluoromethylphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-[4-(3-Nitrophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
N-[3-[4-[4-(3-Formylpyrazolo[1,5-a]pyridin-5-yloxy)butyl]piperazin-1-yl]phenyl]acetamide
5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]-3-hydroxymethylpyrazolo[1,5-a]pyridine
3-Hydroxymethyl-5-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butoxy]methylpyrazolo[1,5-a]pyridine
5-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]-3-hydroxymethylpyrazolo[1,5-a]pyridine
5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]-3-methylpyrazolo[1,5-a]pyridine
5-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]-3-methylpyrazolo[1,5-a]pyridine
5-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]-3-methylpyrazolo[1,5-a]pyridine
3-Aminomethyl-5-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
3-Aminomethyl-5-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridine
3-Aminomethyl-5-[4-[4-(2-chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5a]pyridine
N-[5-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-ylmethyl]acetamide
N-[5-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-ylmethyl]acetamide
N-[5-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]pyrazolo[1,5-a]pyridin-3-ylmethyl]acetamide
5-[4-(4-(2,3-Dihydrobenzofuran-7-yl)piperazin-1-yl)butoxy]pyrazolo[1,5-a]pyridine
5-[4-(4-(Chroman-8-yl)piperazin-1-yl)butoxy]pyrazolo[1,5-a]pyridine
5-[4-(4-(2,3-Dichlorophenyl)-1,4-diazepan-1-yl)butoxy]pyrazolo[1,5-a]pyridine
5-[4-(4-(2-Methoxyphenyl)-1,4-diazepan-1-yl)butoxy]pyrazolo[1,5-a]pyridine
5-[4-(4-(2-Chlorophenyl)-1,4-diazepan-1-yl)butoxy]pyrazolo[1,5-a]pyridine
5-[4-(4-(2,3-Dihydrobenzofuran-7-yl)-1,4-diazepan-1-yl)butoxy]pyrazolo[1,5-a]pyridine
5-[4-(4-(Chroman-8-yl)-1,4-diazepan-1-yl)butoxy]pyrazolo[1,5-a]pyridine
5-[4-(4-(2,3-Dihydrobenzofuran-7-yl)piperazin-1-yl)butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-(4-(Chroman-8-yl)piperazin-1-yl)butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-(4-(2,3-Dichlorophenyl)-1,4-diazepan-1-yl)butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-(4-(2-Methoxyphenyl)-1,4-diazepan-1-yl)butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-(4-(2-Chlorophenyl)-1,4-diazepan-1-yl)butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-(4-(2,3-Dihydrobenzofuran-7-yl)-1,4-diazepan-1-yl)butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
5-[4-(4-(Chroman-8-yl)-1,4-diazepan-1-yl)butoxy]pyrazolo[1,5-a]pyridin-3-carbaldehyde
7-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]indolizine
7-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]indolizine
7-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]indolizine
6-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]imidazo[1,2-a]pyridine
6-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]imidazo[1,2-a]pyridine
6-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]imidazo[1,2-a]pyridine
8-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]imidazo[1,2-a]pyridine
8-[4-[4-(2-Methoxyphenyl)piperazin-1-yl]butoxy]imidazo[1,2-a]pyridine
8-[4-[4-(2-Chlorophenyl)piperazin-1-yl]butoxy]imidazo[1,2-a]pyridine

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A medicine comprising a compound of anyone of claims 1-24.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Pharmaceutical composition comprising a compound of anyone of claims 1-24 and a pharmaceutical acceptable carrier.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Use of a compound according to anyone of claims 1-24 for preparing a medicament for the treatment of a disease selected from psychotic diseases including manic phases of bipolar disorder, acute idiopathic psychotic illnesses, psychoses associated with other diseases, drug-induced psychoses, and schizophrenia; attention deficit hyperactivity disorder (ADHD); autism; bipolar disorder; cognitive impairment; idiopathic or drug-induced movement disorders such as akinesia and dyskinesia; Parkinson's disease; mood disorders including major depressive disorders, substance-induced mood disorders or other forms of depression; anxiety disorders including panic attack, social phobia, or generalized anxiety disorders; obsessive-compulsive disorders; stress-related disorders; addiction disorders; sleep disorders; sexual dysfunction; amnesic and/or cognitive disorders, especially dementia; eating disorders including anorexia and bulemia; pain; and neurodegenerative diseases including Chorea Huntington and multiple sclerosis.

### Claim 28 (depends on 27)

Use according to claim 27, wherein the disease is schizophrenia.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

Method of treating a patient having a disease selected from psychotic diseases including manic phases of bipolar disorder, acute idiopathic psychotic illnesses, psychoses associated with other diseases, drug-induced psychoses, and schizophrenia; attention deficit hyperactivity disorder (ADHD); autism; bipolar disorder; cognitive impairment; idiopathic or drug-induced movement disorders such as akinesia and dyskinesia; Parkinson's disease; mood disorders including major depressive disorders, substance-induced mood disorders or other forms of depression; anxiety disorders including panic attack, social phobia, or generalized anxiety disorders; obsessive-compulsive disorders; stress-related disorders; addiction disorders; sleep disorders; sexual dysfunction; amnesic and/or cognitive disorders, especially dementia; eating disorders including anorexia and bulemia; pain; and neurodegenerative diseases including Chorea Huntington and multiple sclerosis by administering a compound of anyone of claims 1-24.

### Claim 30 (depends on 29)

Method according to claim 29, wherein the disease is schizophrenia.

### Claim 31 (depends on 29, 30)

Method according to claims 29-30, wherein the patient is selected for said treatment of said disease based on a prior diagnosis of said disease.

### Claim 32 (depends on 25)

Kit comprising a medicine according to claim 25, and instructions for its use.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method of producing a compound according to anyone of claims 1-24 comprising the steps of
a. reacting a compound of formula XI with an activated alkylene having the formula XII to give a compound of formula XIII
which compound of formula XIII is then combined with a compound of formula XIV
to give a compound of formula XV
wherein in anyone of formulas XI, XII, XIII, XIV, and XV
R1, Q1, Q2, X, Y, n, R11, q, k, R2, R3, R4, R5, and R6 are as defined in anyone of claims 1-20 for the compounds of formulas I, IIa, IIb, IIc, IId, III, IV, V, VI, VII or VIII; and
W and V are activating groups;
and
(b) optionally adding to the compound of formula XV one or more additional groups R1 to give a compound of anyone of formula I, IIa, IIb, IIc, IId, III, IV, V, VI, VII or VIII according to anyone of claims 1-24.

### Claim 34 (depends on 33)

A method according to claim 33, wherein the activating groups W and V are independently selected from among bromo, chloro, iodine, mesylate, triflate or tosylate.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 33)

A method according to claim 33, wherein in step (b) to a compound of formula XVa an additional group R1′ is added to give a compound of formula XVI, which compound of formula XVI is identical to or can be further transformed into a compound of formula I, IIa, IIb, IIc, IId, III, IV, V, VI, VII or VIII according to anyone of claim 1, 2, 12, 15, 18 or 21
wherein in formulas XVa and XVI
R1′ is selected from among bromo, chloro, iodine, formyl, hydroxymethyl, alkyl, oxime, cyano, aminomethyl, acylaminomethyl; and
R1, Q1, Q3, X and m are as defined in anyone of claims 1-23.

### Claim 36 (depends on 35)

A method of producing a compound of formula XVI according to claim 35 wherein R1′ is selected from among bromo, chloro, iodine and formyl and R1′ is introduced by the reaction of a compound of formula XVa with an activated precursor to get a compound of formula XVI

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 33)

A method according to claim 33, comprising the steps of
(b1) adding to a compound of formula XVa a formyl group to give a compound of formula XVIa
and
(b2) transforming the formyl group of formula XVIa to give a compound of formula XVII which compound of formula XVII is comprised by formula I, IIa, IIb, IIc, IId, III, IV, V, VI, VII or VIII according to anyone of claim 1, 2, 12, 15, 18, or 21,
wherein R1″ is selected from among hydroxymethyl, alkyl, oxime, cyano, aminomethyl and acylaminomethyl,
and Q1, Q3, X and m as defined in any of the claims 1-20.
